Our investments in life sciences companies, including Genting TauRx Diagnostics Centre Sdn Bhd, TauRx Pharmaceuticals Ltd., Celularity Inc., and DNAe Group Holdings Limited, span different stages of research and development aimed at pioneering new treatments and enhancing overall health and lifestyle. Engaging in medical research and development entails elevated risks and an extended gestation period for potential breakthrough discoveries, given the inherent uncertainty in results and success rates. Nevertheless, we maintain an optimistic outlook, believing that these investments will ultimately yield breakthroughs that can significantly enhance and improve the well-being of humanity.

TauRx Pharmaceuticals Ltd’s UK marketing authorisation application for HMTM, an oral anti-tau treatment for Alzheimer’s disease, has been accepted by the UK Medicines and Healthcare products Regulatory Agency and is now under review.

Genting Berhad is building its first stem cell facility, “Fontaine Vitale” in the Sanur Special Economic Zone, Bali, Indonesia which aims to be a world class medical and wellness destination. This will be the first facility in ASEAN to offer placenta-derived allogeneic stem cell therapy through our strategic partnership with Celularity Inc.